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Abstract
Background: Well differentiated neuroendocrine tumours (carcinoids), arising from cells of the diffuse
neuroendocrine system, represent the most commonly encountered gastric endocrine tumours. Gastrointestinal
stromal tumours (GISTs), which stem from interstitial Cajal cells located within the wall of the gastrointestinal tract
and have a characteristic immunoreactivity for CD117 (c-kit protein), account for the majority of gastrointestinal
mesenchymal neoplasms. Simultaneous occurrence of a GIST with a well differentiated neuroendocrine tumour in
the stomach is very rare.
Methods: Clinical history, endoscopy and histopathological findings were utilized for our diagnostic considerations.
Results: We report the coexistence of a high risk GIST with a well differentiated neuroendocrine tumour of benign
clinical behavior, both located in the stomach, in a 62-year-old man previously operated for a gastric well
differentiated neuroendocrine tumour with uncertain malignant behaviour.
Conclusions: Even single well differentiated, sporadic, NETs of small size may coexist with GISTs. An appropriate
initial therapeutic approach combined with a scrupulous follow-up seems to play a significant role in terms of
preventing a metastatic disease.
Background
Gastrointestinal neuroendocrine tumours (NETs) are
thought to derive from cells of the diffuse neuroendo-
crine system of the gastrointestinal (GI) tract [1]. In the
stomach, most endocrine tumours are located in the cor-
pus or fundus, constituting a group of nonfunctioning,
enterochromaffin-like (ECL) cell, well differentiated NETs
(carcinoids). Gastric NETs are divided into four types:
a) type I, associated with autoimmune chronic atrophic
gastritis (A-CAG), b) type II, linked to multiple endocrine
neoplasia type 1 (MEN-1) or to the Zollinger-Ellison
syndrome (ZES) and c) type III, sporadic, unrelated to
hypergastrinemia or A-CAG, d) type IV, representing a
heterogeneous group of tumours which show evidence of
multidirectional differentiation, such as a combination of
adenocarcinoma and NET [2-4].
Gastrointestinal stromal tumours (GISTs) are
mesenchymal neoplasms stemming from the interstitial
cells of Cajal localized within the wall of the GI tract
[5,6]. GISTs show a predilection for the stomach, where
they constitute the majority of mesenchymal tumours
[7,8]. Immunopositivity for CD117 (c-kit protein) is a
distinctive immunohistochemical feature of these
tumours [8,9], for which tumour size and mitotic activ-
ity are the most significant parameters regarding predic-
tion of clinical behavior [10,11].
GISTs have been reported to coexist with a variety of
neoplasms, the percentage of such cases ranging from
4.5% to 33% [12,13]; in such cases, the stomach is the
most frequent location of GIST [12]. The most common
coexisting tumour is adenocarcinoma of the gastroin-
testinal tract [12,13]; other types include lymphoma, leu-
kemia, carcinomas of breast, prostate, pancreas or lung
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studies have shown an association between GI NETs
and synchronous or metachronous epithelial tumours
accounting for about 10% to 46% of cases [17,18].
What is more, coexistence of GISTs with gastrointest-
inal tract endocrine tumours, such as ileal well differen-
tiated NET [19] or well differentiated NET of the
pancreas [14] has also been reported. However, the
simultaneous occurrence of gastric well differentiated
N E Ta n dg a s t r i cG I S Ts e e m st ob er a r e ,ah a n d f u lo f
cases having so far been reported, to our best knowledge
[7,9,12,20].
In this context, we hereby present the case of synchro-
nous occurrence of a GIST and a well differentiated
NET, both located in the stomach of a male patient.
Our report seems to be distinctive as it comprises
unique clinical and histopathological findings.
Case presentation
A 58-year-old male was admitted for chronic muscular
pain. During hospitalization, an episode of melena
occurred, following which he underwent both colono-
scopy and gastroscopy; the latter disclosed an approxi-
mately 1.2 cm large lesion in the greater curvature of
stomach [Figure 1]. A proximal subtotal gastrectomy
(with subsequent reconstruction of the GI tract), includ-
ing the lesion, was therefore performed. A 6.5 × 4.2 × 1
cm surgical specimen containing a mildly protruding,
1 . 2c ml a r g em u c o s a la r e aa tad i s t a n c eo f0 . 8c mf r o m
the closest surgical margin was received; the remaining
mucosa was unremarkable. Histology showed the lesion
to be a completely excised, well differentiated NET with
relatively uniform tumour cells, immunopositive for
chromogranin-A, synaptophysin and CD56; no detect-
able mitoses were seen. The tumour infiltrated both
muscularis mucosae and the contiguous part of the sub-
mucosa. Proliferation index by means of a Ki67/MIB-1
immunostain was lower than 2%. No vascular emboli
were seen. The tumour was therefore classified as a gas-
tric well differentiated NET with uncertain malignant
behaviour [2,21-23]. Adjacent gastric mucosa showed
mild chronic gastritis, diffuse incomplete intestinal
metaplasia of epithelium, as well as endocrine cell
hyperplasia of simple, linear or micronodular types. An
extensive post-operative work-up showed neither signs
of tumour extension, nor serum evidence of autoimmu-
nity; the patient was therefore placed on a regular fol-
low-up. A year later, he underwent another gastroscopy
with biopsies showing chronic inactive gastritis with foci
of diffuse, both complete and incomplete intestinal
metaplasia of the gastric epithelium. Helicobacter pylori
microorganisms were not detected by a Giemsa stain.
However, four years post-op, CT showed a well deli-
neated, 3.5 cm large, intramural lesion in the esophago-
gastric junction. Serum gastrin levels were within
normal limits. The patient underwent excision of the
remaining part of the stomach; this corresponded to a
subtotal gastrectomy (with subsequent reconstruction of
the GI tract) specimen with a 35 cm long greater and a
14.5 cm long lesser curvature, respectively, together
with a 1.9 cm long duodenal cuff. A stenosis was
observed in the incisura angularis; moreover, a protrud-
ing, multilobular, 3.5 cm large tumour was located close
to the esophagogastric junction, on the anterior wall of
the stomach, presenting, upon sections, a whitish color
with brownish foci and a fibrous consistency. The
remaining gastric mucosa was unremarkable.
Histology showed the tumour to consist of interlacing
bundles of spindle cells [Figure 2]. A total number of 15
mitoses per 50 high power fields (with a ×40 objective)
were assessed in the most cellular neoplastic areas. The
tumour contained areas of hemorrhagic infiltration or
cystic degeneration and had mainly pushing borders.
Neoplastic cells were intensely decorated with antibodies
against CD117/c-kit [Figure 2], CD34 and vimentin,
were focally immunoreactive for a-SMA and S-100 pro-
tein, but did not stain for cytokeratin 18. Proliferation
i n d e xb ym e a n so faK i 6 7 / M I B - 1i m m u n o s t a i nw a s
approximately 10%, with predominant staining in per-
ipheral tumour areas. Consequently, a diagnosis of mod-
erate risk GIST (based on criteria laid down by the
Armed Forces Institute of Pathology) [11] or high risk
GIST (based on the National Institute of Health GIST
Workshop-2001) [10] was established.
Moreover, in the stenotic area of the incisura angularis
(vide supra), a totally excised, 0.4 cm large, well differ-
entiated NET of benign clinical behavior was identified:
Figure 1 Gastroscopy; an approximately 1.2 cm large lesion in
the greater curvature of stomach. Note the smooth contour of
the mildly protruding lesion as well as its bleeding even with gentle
endoscopic manipulations.
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sisted of a monomorphic cellular population, with
inconspicuous mitotic activity, forming adenoid or solid
aggregates [Figure 3]. An Alcian blue stain disclosed no
mucin. Tumour cells were immunoreactive for chromo-
granin-A [Figure 3] and synaptophysin, but not for
CD56 or serotonin. The proliferation (Ki-67/MIB-1)
index was approximately 2%. No vascular emboli were
seen. The adjacent gastric mucosa showed atrophic gas-
tritis along with extensive complete intestinal metaplasia
[Figure 3]. Giemsa stain disclosed no Helicobacter
pylori. Thus, on the basis of recent data suggesting a
role of adjuvant imatinib therapy in terms of improving
recurrence-free survival after the resection of primary
localized GIST, the patient was placed on imatinib [24];
he is alive and well a year after the second operation.
Conclusions
Of the previous reports regarding the simultaneous
occurence of GIST and well differentiated NET in the
stomach we achieved to retrieve data only for three
cases. Specifically, one case concerned a 69-year old
male with negative family history of cancer who under-
went removal of a sessile polypoid mass in the corpus of
the stomach. Histological examination of the resected
specimen demonstrated a submucosal borderline GIST,
while in the overlying mucosa a well differentiated NET
(carcinoid), invading the lamina propria and initially
infiltrating the submucosa, was recognized. Neither H.
pylori microorganisms nor foci of intestinal metaplasia
were identified in the surrounding mucosa. The patient
died of unrelated cause (heart attack) twelve months
after the surgical intervention, while imaging findings
were all negative concerning metastatic deposits from
the above-mentioned lesions [20].
T h es e c o n dc a s ec o n c e r n e da6 5 - y e a r - o l df e m a l ew i t h
a low-risk GIST on the anterior wall of the upper gastric
corpus concomitant with a type III well differentiated
NET localized on the posterior wall of the upper gastric
corpus; no recurrence of either tumour occurred 28
months after excision [9]. In the third case a 65-year-old
female, who had previously undergone subtotal gastrect-
omy for a GIST (risk category not mentioned), pre-
sented with serum hypergastrinemia and polypoid
lesions of the gastric stump, a year post-op. Histology
showed polypoid type I gastric well differentiated NETs,
while the histopathological examination of the remain-
ing stomach’s excision specimen documented the co-
existence of a GIST (risk category not mentioned) [7].
Agaimy et al., also, based on their own archives and on
data collected from the literature, reported four gastric
well differentiated NETs concurrent with GISTs [12].
Regarding pathogenetic mechanisms implicated in the
dual development of GIST andw e l ld i f f e r e n t i a t e dN E T
in the stomach, data are still insufficient. Though a role
of H. pylori infection cannot be excluded, it is at present
not clear, perhaps due to the small number of cases so
far reported. Thus, Lin et al. did not conclude any defi-
nite causal relationship among GIST, well differentiated
NET and H. pylori infection [9], a point also valid in
our case, where no H. pylori was shown. The hypothesis
which is based on experimental data in rats and sup-
ports the notion that a single carcinogenic agent possi-
bly interacts with two neighboring tissues, inducing the
development of tumours of different histotypes in the
Figure 2 GIST of the stomach.F i g . 2 a( H e m a t o x y l i n - E o s i n / X 1 0 ) :
Neoplastic growth pattern characterized by interlacing bundles of
spindle cells with focal mitotic activity. Fig.2b (anti-CD117/X20):
Diffuse immunoreactivity of neoplastic cells.
Figure 3 The second well differentiated neuroendocrine
tumour of the stomach. Fig.3a (Hematoxylin-Eosin/X10): Neoplasm
localized in the mucosa and submucosa and consisted of
monomorphous cells, with unremarkable mitotic activity, forming
adenoid or solid aggregates. Note adjacent gastric glands with areas
of intestinal metaplasia. Fig.3b (anti-Chromogranin/X20): Diffuse,
intense, immunoexpression by tumour cells.
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sues [25-27]. In addition, we cannot entirely exclude the
possibility that genetic factors concerning specific gene
mutations could be responsible for the synchronous
development of two gastric tumours. On the other
hand, a coincidental growth of two primary neoplasms
in the same organ (stomach) could be also a possible
consideration. Further studies are certainly needed in
order to elucidate this phenomenon.
Gastric well differentiated NETs account for 8.7-41%
of all gastrointestinal well differentiated NETs [2]. Their
clinical features include abdominal pain, vomiting, ane-
mia, massive gastric bleeding or, rarely, carcinoid
syndrome [2,27]. Our patient had an episode of melena
preceding the diagnosis of its first well differentia-
ted NET, whereas the second one was incidentally
diagnosed.
In our report, both well differentiated NETs were sin-
g l el e s i o n s ;d e s p i t et h ef a c tt h a tt h ef i r s tt u m o u ra r o s e
in the context of endocrine cell hyperplasia, the absence
of serum autoimmunity indices precludes its classifica-
tion as a type I gastric well differentiated NET; both
tumours, therefore, correspond to type III according to
the WHO classification [2-4].
According to the WHO classification, benign behavior
of well differentiated NETs is associated with the follow-
ing criteria: cytologically bland tumour confined to
mucosa and/or submucosa, non-angioinvasive, less than
1 cm in size, non-functioning; these features are mainly
found in tumours arising in the context of A-CAG or
MEN-1/ZES. On the contrary, uncertain malignant
behavior of well differentiated NETs is associated with a
nonfunctioning, cytologically bland tumour, measuring 1
to 2 cm in diameter, confined to the mucosa and/or
submucosa. Angioinvasion may be present in these
lesions [2,21-23]. This category comprises some of the
type II gastric NETs. Therefore, in our case, the first
neuroendocrine tumour was diagnosed with uncertain
malignant behaviour due to its size and its being single.
Limited surgical interventions (including endoscopic
manipulations) remain the mainstay treatment for type I
gastric well differentiated NETs [28]. Partial gastrectomy
combined with appropriate treatment for concomitant
hypergastrinemia is necessary for type II neoplasms [29].
Finally, a total gastrectomy is counseled for type III well
differentiated NETs, even when they are histologically
well differentiated, particularly in tumours larger than 1
cm [2,29], a treatment not initially performed in our
case, due to the patient’s refusal.
GISTs, thought to arise from interstitial Cajal cells of
the gastrointestinal wall [5,6], demonstrate no clear gen-
der predilection; affected individuals are mainly adults
between the 6th and 8th decade [8]. Gastric GISTs can
be incidentally detected during endoscopy, an imaging
study or in a surgical specimen, given that they are
slowly growing tumours localized within deeper layers
of gastrointestinal wall. Though our patient was asymp-
tomatic, GISTs usually manifest with nonspecific symp-
toms, such as nausea, vomiting, abdominal pain or,
most often, with bleeding, due to protrusion of the
tumour and stretching of the overlying mucosa; metas-
tasis may sometimes constitute the initial symptom
[8,9].
Optimal therapy includes surgical excision and treat-
ment with imatinib. The latter is appropriate for non-
operable tumours, cases where total excision is impossible
or for recurrences [9,30].
Concerning prediction of clinical behavior, the initial
proposal formulated by the National Institute of Health
(NIH) GIST Workshop in 2001 defined the risk for
aggressive behavior based on tumour size (single largest
dimension) and mitotic count (number of mitotic fig-
ures per 50 HPF) [10], classifying GISTs into very low,
low, intermediate and high risk categories. More
recently, the Armed Forces Institute of Pathology (AFIP)
suggested a new risk stratification of primary GISTs,
introducing the site involved alongside the two criteria
previously mentioned, i.e. mitotic index and size [11];
thus, gastric GISTs are stratified as having none, very
low, low, moderate or high risk of progressive disease.
Regardless of the system used, it should be kept in mind
that large tumours (especially those larger than 10 cm),
even when having no detectable mitotic activity, may
show late recurrences and even metastatic deposits.
According to the WHO guidelines, DNA-aneuploidy
and high proliferative activity, assessed by proliferation
markers, may reflect higher malignant potential [8]. In
our case, the GIST was classified as of moderate risk
according to the AFIP criteria, whereas it corresponded
to the high risk category according to the NIH criteria.
I nc o n c l u s i o n ,w ep r e s e n t e dar a r ec a s eo faw e l ld i f -
ferentiated NET concurrent with a GIST in the sto-
mach. Gastroenterologists and pathologists, in
particular, should be aware of this rare phenomenon
given that even single well differentiated, sporadic (unre-
lated to hypergastrinemia or A-CAG), NETs of small
size may coexist with GISTs, as it was shown in our
case. A meticulous follow-up (along with a well sched-
uled initial therapeutic approach) should be performed
to all patients suffering from the afore-mentioned neo-
plasms so as the devastating consequences of a meta-
static disease to be avoided.
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